Keyphrases
Multiple Myeloma
99%
Diffuse Large B-cell Lymphoma (DLBCL)
81%
Non-Hodgkin Lymphoma
78%
Rituximab
67%
Overall Survival
54%
B-cell non-Hodgkin Lymphoma (B-NHL)
54%
Lymphoma
48%
Myeloma
43%
Lenalidomide
43%
Phase II Trial
42%
Relapsed or Refractory
40%
Follicular Lymphoma
39%
Waldenström Macroglobulinemia
38%
Chronic Lymphocytic Leukemia
34%
90Y-ibritumomab Tiuxetan
34%
Radioimmunotherapy
31%
Mantle Cell Lymphoma
31%
Plasma Cells
29%
Confidence Interval
29%
Mayo Clinic
29%
Newly Diagnosed
28%
Thalidomide
27%
Progression-free Survival
27%
Bone Marrow
27%
Complete Response
27%
Overall Response Rate
24%
Prognostic Factors
23%
Clinical Trials
23%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
23%
Myeloma Cells
23%
Peripheral Blood
23%
Initial Treatment
22%
Lymphoma Patients
21%
Cyclophosphamide
20%
Phase II Study
20%
Angiogenesis
19%
Primary Systemic Amyloidosis
19%
Hazard Ratio
19%
Event-free Survival
19%
B Cells
19%
Time to Progression
18%
Chemotherapy
17%
Partial Response
16%
R-CHOP
15%
Relapsed or Refractory multiple Myeloma
15%
Median Time
15%
Prednisone
15%
Tumor
15%
Everolimus
15%
Newly Diagnosed multiple Myeloma
15%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
87%
Multiple Myeloma
85%
Disease
81%
Non-Hodgkin Lymphoma
63%
Overall Survival
63%
Plasma Cell
54%
B Cell
48%
Rituximab
45%
Lenalidomide
39%
Mantle Cell Lymphoma
36%
B-Cell Chronic Lymphocytic Leukemia
36%
Follicular Lymphoma
36%
Waldenström's Macroglobulinemia
34%
Neoplasm
33%
Myeloma
32%
Progression Free Survival
29%
Lymphocyte
26%
Prognostic Factor
23%
Clinical Trial
22%
Light Chain
21%
Event Free Survival
21%
Amyloidosis
20%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
19%
Drug Megadose
18%
Hodgkin's Lymphoma
17%
Everolimus
16%
Monoclonal Gammopathy of Undetermined Significance
16%
Hazard Ratio
16%
Autologous Stem Cell Transplantation
15%
Radioimmunotherapy
14%
Phase II Trials
14%
Dexamethasone
13%
AL Amyloidosis
13%
Ibritumomab Tiuxetan
13%
Biopsy
13%
Cyclophosphamide
12%
Smouldering Myeloma
12%
Flow Cytometry
12%
T Cell
12%
Cancer Therapy
12%
Multivariate Analysis
11%
Radiation Therapy
11%
Prednisone
11%
Adverse Event
11%
Angiogenesis
11%
Stem Cell Transplant
11%
Molecular Epidemiology
11%
Doxorubicin
11%
B-Cell Lymphoma
10%
Disease Exacerbation
10%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Rituximab
77%
Multiple Myeloma
68%
Disease
57%
Ibritumomab Tiuxetan
52%
Overall Survival
47%
Diffuse Large B Cell Lymphoma
47%
Lenalidomide
43%
Yttrium 90
39%
Progression Free Survival
38%
Dexamethasone
37%
Mantle Cell Lymphoma
34%
Follicular Lymphoma
32%
Myeloma
31%
Malignant Neoplasm
30%
Chronic Lymphatic Leukemia
30%
Neoplasm
28%
Chemotherapy
28%
Phase II Trials
26%
Clinical Trial
24%
Thalidomide
21%
Remission
21%
Cyclophosphamide
19%
Everolimus
18%
Amyloidosis
17%
Adverse Event
17%
Waldenstroem macroglobulinemia
16%
Event Free Survival
15%
Thrombocytopenia
13%
Prednisone
13%
Bortezomib
13%
Cytokine
12%
Mammalian Target of Rapamycin Inhibitor
12%
Cladribine
11%
Temsirolimus
10%
Neutropenia
10%
Combination Therapy
9%
AL Amyloidosis
9%
Hodgkin Disease
9%
Melphalan
9%
Vincristine
9%
Phase I Trials
9%
Anemia
8%
Biological Marker
8%
Placebo
8%
Doxorubicin
8%
Monotherapy
8%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
7%
Recurrent Disease
7%
Bendamustine
7%